U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Recurrent Oligodendroglioma

MedGen UID:
1689746
•Concept ID:
C5203000
•
Neoplastic Process

Definition

The reemergence of oligodendroglioma after a period of remission. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVRecurrent Oligodendroglioma

Professional guidelines

PubMed

1p/19q loss within oligodendroglioma is predictive for response to first line temozolomide but not to salvage treatment.
Kouwenhoven MC, Kros JM, French PJ, Biemond-ter Stege EM, Graveland WJ, Taphoorn MJ, Brandes AA, van den Bent MJ
Eur J Cancer 2006 Oct;42(15):2499-503. Epub 2006 Aug 17 doi: 10.1016/j.ejca.2006.05.021. PMID: 16914310
Current diagnosis and treatment of oligodendroglioma.
Engelhard HH
Neurosurg Focus 2002 Feb 15;12(2):E2. doi: 10.3171/foc.2002.12.2.3. PMID: 16212319
Hypofractionated stereotactic radiotherapy in the management of recurrent glioma.
Shepherd SF, Laing RW, Cosgrove VP, Warrington AP, Hines F, Ashley SE, Brada M
Int J Radiat Oncol Biol Phys 1997 Jan 15;37(2):393-8. doi: 10.1016/s0360-3016(96)00455-5. PMID: 9069312

Recent clinical studies

Etiology

Phase I-II trial of imatinib mesylate (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. North central cancer treatment group study N0272 (ALLIANCE/NCCTG).
Jaeckle KA, Anderson SK, Twohy EL, Dixon JG, Giannini C, Jenkins R, Egorin MJ, Sarkaria JN, Brown PD, Flynn PJ, Schwerkoske J, Buckner JC, Galanis E
J Neurooncol 2019 Jul;143(3):573-581. Epub 2019 May 22 doi: 10.1007/s11060-019-03194-z. PMID: 31119479Free PMC Article
Salvage PCV chemotherapy for temozolomide-resistant oligodendrogliomas.
Triebels VH, Taphoorn MJ, Brandes AA, Menten J, Frenay M, Tosoni A, Kros JM, Stege EB, Enting RH, Allgeier A, van Heuvel I, van den Bent MJ
Neurology 2004 Sep 14;63(5):904-6. doi: 10.1212/01.wnl.0000137049.65631.db. PMID: 15365146
Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972.
van den Bent MJ, Chinot O, Boogerd W, Bravo Marques J, Taphoorn MJ, Kros JM, van der Rijt CC, Vecht CJ, De Beule N, Baron B
Ann Oncol 2003 Apr;14(4):599-602. doi: 10.1093/annonc/mdg157. PMID: 12649108
Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU, and vincristine chemotherapy. Dutch Neuro-oncology Group.
van den Bent MJ, Kros JM, Heimans JJ, Pronk LC, van Groeningen CJ, Krouwer HG, Taphoorn MJ, Zonnenberg BA, Tijssen CC, Twijnstra A, Punt CJ, Boogerd W
Neurology 1998 Oct;51(4):1140-5. doi: 10.1212/wnl.51.4.1140. PMID: 9781544
Recurrent oligodendroglioma diagnosed with 11C-L-methionine and PET: a case report.
Viader F, Derlon JM, Petit-Taboué MC, Shishido F, Hubert P, Houtteville JP, Courtheoux P, Chapon F
Eur Neurol 1993;33(3):248-51. doi: 10.1159/000116947. PMID: 8467848

Diagnosis

PTPRD and CNTNAP2 as markers of tumor aggressiveness in oligodendrogliomas.
Rautajoki KJ, Jaatinen S, Tiihonen AM, Annala M, Vuorinen EM, Kivinen A, Rauhala MJ, Maass KK, Pajtler KW, Yli-Harja O, Helén P, Haapasalo J, Haapasalo H, Zhang W, Nykter M
Sci Rep 2022 Aug 18;12(1):14083. doi: 10.1038/s41598-022-14977-2. PMID: 35982066Free PMC Article
Recurrent Oligodendroglioma Treated with Acupuncture and Pharmacopuncture.
Kim JS, Lee HJ, Lee SH, Lee BH
J Acupunct Meridian Stud 2015 Jun;8(3):147-51. Epub 2015 Apr 24 doi: 10.1016/j.jams.2015.03.004. PMID: 26100069
Disseminated spread of recurrent oligodendroglioma (WHO grade II).
Ng WH, Lim TC, Tan KK
J Clin Neurosci 2006 Jun;13(5):602-7. Epub 2006 May 12 doi: 10.1016/j.jocn.2005.05.020. PMID: 16697645
Current diagnosis and treatment of oligodendroglioma.
Engelhard HH
Neurosurg Focus 2002 Feb 15;12(2):E2. doi: 10.3171/foc.2002.12.2.3. PMID: 16212319
Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU, and vincristine chemotherapy. Dutch Neuro-oncology Group.
van den Bent MJ, Kros JM, Heimans JJ, Pronk LC, van Groeningen CJ, Krouwer HG, Taphoorn MJ, Zonnenberg BA, Tijssen CC, Twijnstra A, Punt CJ, Boogerd W
Neurology 1998 Oct;51(4):1140-5. doi: 10.1212/wnl.51.4.1140. PMID: 9781544

Therapy

Recurrent oligodendroglioma with changed 1p/19q status.
Barresi V, Mafficini A, Calicchia M, Piredda ML, Musumeci A, Ghimenton C, Scarpa A
Neuropathology 2022 Apr;42(2):160-166. Epub 2022 Feb 10 doi: 10.1111/neup.12789. PMID: 35144313Free PMC Article
Comparative molecular analysis of primary and recurrent oligodendroglioma that acquired imbalanced 1p/19q codeletion and TP53 mutation: a case report.
Ono T, Reinhardt A, Takahashi M, Nanjo H, Kamataki A, von Deimling A, Shimizu H
Acta Neurochir (Wien) 2020 Dec;162(12):3019-3024. Epub 2020 Aug 12 doi: 10.1007/s00701-020-04514-3. PMID: 32785787
Recurrent Oligodendroglioma Treated with Acupuncture and Pharmacopuncture.
Kim JS, Lee HJ, Lee SH, Lee BH
J Acupunct Meridian Stud 2015 Jun;8(3):147-51. Epub 2015 Apr 24 doi: 10.1016/j.jams.2015.03.004. PMID: 26100069
Carboplatin and teniposide as third-line chemotherapy in patients with recurrent oligodendroglioma or oligoastrocytoma: a phase II study.
Brandes AA, Basso U, Vastola F, Tosoni A, Pasetto LM, Jirillo A, Lonardi S, Paris MK, Koussis H, Monfardini S, Ermani M
Ann Oncol 2003 Dec;14(12):1727-31. doi: 10.1093/annonc/mdg494. PMID: 14630676
Temozolomide chemotherapy in recurrent oligodendroglioma.
van den Bent MJ, Keime-Guibert F, Brandes AA, Taphoorn MJ, Kros JM, Eskens FA, Carpentier AF
Neurology 2001 Jul 24;57(2):340-2. doi: 10.1212/wnl.57.2.340. PMID: 11468326

Prognosis

PTPRD and CNTNAP2 as markers of tumor aggressiveness in oligodendrogliomas.
Rautajoki KJ, Jaatinen S, Tiihonen AM, Annala M, Vuorinen EM, Kivinen A, Rauhala MJ, Maass KK, Pajtler KW, Yli-Harja O, Helén P, Haapasalo J, Haapasalo H, Zhang W, Nykter M
Sci Rep 2022 Aug 18;12(1):14083. doi: 10.1038/s41598-022-14977-2. PMID: 35982066Free PMC Article
Phase I-II trial of imatinib mesylate (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. North central cancer treatment group study N0272 (ALLIANCE/NCCTG).
Jaeckle KA, Anderson SK, Twohy EL, Dixon JG, Giannini C, Jenkins R, Egorin MJ, Sarkaria JN, Brown PD, Flynn PJ, Schwerkoske J, Buckner JC, Galanis E
J Neurooncol 2019 Jul;143(3):573-581. Epub 2019 May 22 doi: 10.1007/s11060-019-03194-z. PMID: 31119479Free PMC Article
Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a prospective GICNO study.
Brandes AA, Tosoni A, Cavallo G, Reni M, Franceschi E, Bonaldi L, Bertorelle R, Gardiman M, Ghimenton C, Iuzzolino P, Pession A, Blatt V, Ermani M; GICNO
J Clin Oncol 2006 Oct 10;24(29):4746-53. Epub 2006 Sep 5 doi: 10.1200/JCO.2006.06.3891. PMID: 16954518
Disseminated spread of recurrent oligodendroglioma (WHO grade II).
Ng WH, Lim TC, Tan KK
J Clin Neurosci 2006 Jun;13(5):602-7. Epub 2006 May 12 doi: 10.1016/j.jocn.2005.05.020. PMID: 16697645
Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU, and vincristine chemotherapy. Dutch Neuro-oncology Group.
van den Bent MJ, Kros JM, Heimans JJ, Pronk LC, van Groeningen CJ, Krouwer HG, Taphoorn MJ, Zonnenberg BA, Tijssen CC, Twijnstra A, Punt CJ, Boogerd W
Neurology 1998 Oct;51(4):1140-5. doi: 10.1212/wnl.51.4.1140. PMID: 9781544

Clinical prediction guides

Phase I-II trial of imatinib mesylate (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. North central cancer treatment group study N0272 (ALLIANCE/NCCTG).
Jaeckle KA, Anderson SK, Twohy EL, Dixon JG, Giannini C, Jenkins R, Egorin MJ, Sarkaria JN, Brown PD, Flynn PJ, Schwerkoske J, Buckner JC, Galanis E
J Neurooncol 2019 Jul;143(3):573-581. Epub 2019 May 22 doi: 10.1007/s11060-019-03194-z. PMID: 31119479Free PMC Article
Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a prospective GICNO study.
Brandes AA, Tosoni A, Cavallo G, Reni M, Franceschi E, Bonaldi L, Bertorelle R, Gardiman M, Ghimenton C, Iuzzolino P, Pession A, Blatt V, Ermani M; GICNO
J Clin Oncol 2006 Oct 10;24(29):4746-53. Epub 2006 Sep 5 doi: 10.1200/JCO.2006.06.3891. PMID: 16954518
Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972.
van den Bent MJ, Chinot O, Boogerd W, Bravo Marques J, Taphoorn MJ, Kros JM, van der Rijt CC, Vecht CJ, De Beule N, Baron B
Ann Oncol 2003 Apr;14(4):599-602. doi: 10.1093/annonc/mdg157. PMID: 12649108
Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU, and vincristine chemotherapy. Dutch Neuro-oncology Group.
van den Bent MJ, Kros JM, Heimans JJ, Pronk LC, van Groeningen CJ, Krouwer HG, Taphoorn MJ, Zonnenberg BA, Tijssen CC, Twijnstra A, Punt CJ, Boogerd W
Neurology 1998 Oct;51(4):1140-5. doi: 10.1212/wnl.51.4.1140. PMID: 9781544
Hypofractionated stereotactic radiotherapy in the management of recurrent glioma.
Shepherd SF, Laing RW, Cosgrove VP, Warrington AP, Hines F, Ashley SE, Brada M
Int J Radiat Oncol Biol Phys 1997 Jan 15;37(2):393-8. doi: 10.1016/s0360-3016(96)00455-5. PMID: 9069312

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...